The Lancet Infectious Diseases journal, which based its findings on estimates of “excess” mortalities in the country during the pandemic.
The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.
Further 599,300 lives could have been saved if the World Health Organization's target of vaccinating 40 per cent of the population in each country with two or more doses by end of 2021 had been met.
An committee member said it has been resolved that four of the five departments would admit candidates by awarding equal weightage to tests and Plus-2 marks.
The expert panel in its last meeting in April had sought more data from SII following its application seeking the emergency use authorization of Covovax for seven to 11 years.
The wild version of the virus now exists only in Afghanistan and Pakistan, but a type of vaccine that contains small amounts of weakened but live polio still causes occasional outbreaks elsewhere.
India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
"This is a great progress for Quad Vaccine and the US India Health partnership," said a US Embassy spokesperson.
A 17-year-old girl who lost eyesight a day after she was administered with Covid vaccine at a Ranipet school sought the government’s help to study medicine.
Delhi reports 1,797 fresh cases on Friday a 35 per cent jump over previous day’s tally, city now has 4,843 active cases.
Despite the surge in Covid-19 cases sparking some concern, Delhi residents have not shown much enthusiasm to get the booster shot.
The regulatory body has now approved Moderna shots for school-aged children and teens as well.
Friday's compromise fell short of their earlier requests that the waiver apply to all countries -- and also cover Covid tests and treatments.
A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal.
The panel members found a lack of uniformity in results upon mixing of jabs for booster shots and stated that no recommendation for it can be made as of now.